Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$519K Buy
18,482
+945
+5% +$25.2K 0.31% 54
2025
Q4
$437K Buy
17,537
+851
+5% +$21.5K 0.29% 80
2025
Q3
$425K Buy
16,686
+4,208
+34% +$104K 0.3% 72
2025
Q2
$302K Buy
+12,478
New +$291K 0.28% 96
2025
Q1
Sell
-3,788
Closed -$101K 602
2024
Q4
$101K Sell
3,788
-17,453
-82% -$473K 0.07% 174
2024
Q3
$568K Sell
21,241
-762
-3% -$22.2K 0.35% 65
2024
Q2
$616K Buy
22,003
+17,213
+359% +$474K 0.44% 58
2024
Q1
$133K Buy
4,790
+1,751
+58% +$48.6K 0.1% 140
2023
Q4
$87.5K Buy
+3,039
New +$91.9K 0.07% 151

Other funds holding PFE

Caitlin John's PFE Position: Q1 2026 in Review

Caitlin John increased its Pfizer (PFE) stake by 5.4% in Q1 2026, buying an estimated $25.2K and bringing the position to 18,482 shares worth $519K. The position accounts for 0.31% of the portfolio, ranked #54.

Caitlin John first reported a position in PFE in Q4 2023 and has held it in 9 quarters since. The position peaked at $616K in Q2 2024. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Caitlin John held 18,482 shares of Pfizer worth $519K as of Q1 2026.
  • Caitlin John bought 945 Pfizer shares in Q1 2026, an estimated $25.2K.
  • Pfizer made up 0.31% of Caitlin John's portfolio in Q1 2026, its #54 holding.
  • Caitlin John first reported a position in Pfizer in Q4 2023 and has held it in 9 quarters since.
  • Caitlin John's Pfizer position peaked at $616K in Q2 2024.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.